文献速递乳腺乳腺X线MR

对比增强乳腺X线摄影与对比增强乳腺MRI的系统综述与荟萃分析

Contrast-enhanced Mammography versus Contrast-enhanced Breast MRI: A Systematic Review and Meta-Analysis.
PubMed 文献 · Radiology · 2022-06-07

该系统综述与荟萃分析比较了对比增强乳腺X线摄影(CEM)与对比增强MRI(CE-MRI)在检测乳腺癌中的诊断性能。纳入7项研究共1137个病灶,CE-MRI灵敏度更高(97% vs 91%,P < .001),但特异度略低(69% vs 74%,P = .09)。CE-MRI的阴性似然比更低(0.04 vs 0.12),且能在更高的验前概率(33% vs 14%)下排除乳腺癌。

要点

  • CE-MRI灵敏度高于CEM(97% vs 91%),但特异度两者差异无统计学意义。
  • CE-MRI阴性似然比更低(0.04 vs 0.12),排除乳腺癌的能力更强。
  • CEM可在验前概率≤14%时排除乳腺癌,CE-MRI可在≤33%时排除。

诊断标准与关键数值

  • CE-MRI灵敏度97%(95%CI:86,99),CEM灵敏度91%(95%CI:77,97),P < .001。
  • CE-MRI特异度69%(95%CI:46,85),CEM特异度74%(95%CI:52,89),P = .09。
  • CE-MRI阳性似然比3.1,CEM阳性似然比3.6;CE-MRI阴性似然比0.04,CEM阴性似然比0.12。
  • Fagan列线图显示,CE-MRI可在验前概率≤33%时排除乳腺癌,CEM可在≤14%时排除。
  • 碘浓度与CEM灵敏度正相关(P = .04),与特异度负相关(P < .001)。

临床应用与阅片要点

  • 在需要高灵敏度排除乳腺癌的场景(如高验前概率),CE-MRI应作为首选功能成像方法。
  • CEM可作为CE-MRI不可及时的可选方案,但其排除恶性的验前概率阈值较低(14%)。
  • 考虑将BI-RADS 4类降级为3类时,需注意CE-MRI和CEM的验前概率上限分别为33%和14%。

局限性

  • 纳入研究数量较少(仅7项),可能影响结果的稳健性。
  • 平均癌症患病率高达65.3%,存在谱偏倚可能,外推至低患病率人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Contrast-enhanced mammography (CEM) is a more accessible alternative to contrast-enhanced MRI (CE-MRI) in breast imaging, but a summary comparison of published studies is lacking. Purpose To directly compare the performance of CEM and CE-MRI regarding sensitivity, specificity, and negative predictive value in detecting breast cancer, involving all publicly available studies in the English language. Materials and Methods Two readers extracted characteristics of studies investigating the comparative diagnostic performance of CEM and CE-MRI in detecting breast cancer. Studies published until April 2021 were eligible. Sensitivity, specificity, negative predictive value, and positive and negative likelihood ratios were calculated using bivariate random effects models. A Fagan nomogram was used to identify the maximum pretest probability at which posttest probabilities of a negative CEM or CE-MRI examination were in line with the 2% malignancy rate benchmark for downgrading a Breast Imaging Reporting and Data System (BI-RADS) category 4 to a BI-RADS category 3 result. I 2 statistics, Deeks funnel plot asymmetry test for publication bias, and meta-regression were used. Results Seven studies investigating 1137 lesions (654 malignant, 483 benign) with an average cancer prevalence of 65.3% (range: 47.3%-82.2%) were included. No publication bias was found (P = .57). While the positive likelihood ratio was equal at a value of 3.1 for CE-MRI and 3.6 for CEM, the negative likelihood ratio of CE-MRI (0.04) was lower than that with CEM (0.12). CE-MRI had higher sensitivity for breast cancer than CEM (97% [95% CI: 86, 99] vs 91% [95% CI: 77, 97], respectively; P < .001) but lower specificity (69% [95% CI: 46, 85] vs 74% [95% CI: 52, 89]; P = .09). A Fagan nomogram demonstrated that the maximum pretest probability at which both tests could rule out breast cancer was 33% for CE-MRI and 14% for CEM. Furthermore, iodine concentration was positively associated with CEM sensitivity and negatively associated with its specificity (P = .04 and P < .001, respectively). Conclusion Contrast-enhanced MRI had superior sensitivity and negative likelihood ratios with higher pretest probabilities to rule out malignancy compared with contrast-enhanced mammography. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Mann and Veldhuis in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Pötsch, Vatteroni, Clauser, et al. Contrast-enhanced Mammography versus Contrast-enhanced Breast MRI: A Systematic Review and Meta-Analysis. Radiology. 2022. PMID: 36154284. doi:10.1148/radiol.212530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。